سعر سيردالود 2مجم 20 قرص 2024

Sirdalud 2 mg tablets, pack of 20 (Novartis/Sandoz): tizanidine, a centrally acting alpha-2 adrenergic agonist muscle relaxant.

• Management of spasticityPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions: dry mouth, somnolence, asthenia and dizziness (each >10% and more than placebo).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant use with potent CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin; hypersensitivity to tizanidine or its ingredients.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypotension, including syncope; risk increased with antihypertensives, CYP1A2 inhibitors and dose escalation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Risk of liver injury: monitor aminotransferases at baseline and 1 month after maximum dose is reached, or if liver injury is suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Sedation (additive with alcohol and CNS depressants); hallucinations and psychotic-like symptoms; hypersensitivity including anaphylaxis; withdrawal adverse reactions (rebound hypertension, tachycardia, hypertonia) on abrupt discontinuation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Fluvoxamine, ciprofloxacin (potent CYP1A2 inhibitors)Markedly increased tizanidine exposure with significant hypotension and sedation; contraindicated.DailyMed (U.S. National Library of Medicine)
• Moderate or weak CYP1A2 inhibitors (e.g. zileuton, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine)Concomitant use should be avoided; if clinically necessary and hypotension, bradycardia or excessive drowsiness occur, reduce the tizanidine dosage or discontinue it.DailyMed (U.S. National Library of Medicine)
• Oral contraceptivesConcomitant use is not recommended; if clinically necessary and hypotension, bradycardia or excessive drowsiness occur, reduce or discontinue tizanidine.DailyMed (U.S. National Library of Medicine)

• There are no adequate data on the developmental risk of tizanidine in pregnant women; in animal studies, tizanidine during pregnancy caused developmental toxicity (embryofetal and postnatal offspring mortality and growth deficits) at doses less than those used clinically.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant or milk production; weigh benefits against potential adverse effects.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Tizanidine: Central alpha-2 adrenergic agonist; presumably reduces spasticity by increasing presynaptic inhibition of motor neurons.